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BACKGROUND
Long-acting injectable regimens may simplify therapy for patients with human 
immunodeficiency virus type 1 (HIV-1) infection.
METHODS
We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 
infection who had not previously received antiretroviral therapy were given 20 
weeks of daily oral induction therapy with dolutegravir–abacavir–lamivudine. Par-
ticipants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 
weeks were randomly assigned (1:1) to continue the current oral therapy or switch 
to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of 
long-acting cabotegravir plus rilpivirine. The primary end point was the percent-
age of participants who had an HIV-1 RNA level of 50 copies per milliliter or 
higher at week 48 (Food and Drug Administration snapshot algorithm).
RESULTS
At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 
6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 
(2.5%) who received oral therapy (adjusted difference, −0.4 percentage points; 95% 
confidence interval [CI], −2.8 to 2.1), a result that met the criterion for noninferior-
ity for the primary end point (margin, 6 percentage points). An HIV-1 RNA level 
of less than 50 copies per milliliter at week 48 was found in 93.6% who received 
long-acting therapy and in 93.3% who received oral therapy (adjusted difference, 
0.4 percentage points; 95% CI, −3.7 to 4.5), a result that met the criterion for non-
inferiority for this end point (margin, −10 percentage points). Of the participants 
who received long-acting therapy, 86% reported injection-site reactions (median 
duration, 3 days; mild or moderate severity, 99% of cases); 4 participants withdrew 
from the trial for injection-related reasons. Grade 3 or higher adverse events and 
events that met liver-related stopping criteria occurred in 11% and 2%, respec-
tively, who received long-acting therapy and in 4% and 1% who received oral 
therapy. Treatment satisfaction increased after participants switched to long-acting 
therapy; 91% preferred long-acting therapy at week 48.
CONCLUSIONS
Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral 
therapy with dolutegravir–abacavir–lamivudine with regard to maintaining HIV-1 
suppression. Injection-site reactions were common. (Funded by ViiV Healthcare 
and Janssen; FLAIR ClinicalTrials.gov number, NCT02938520.)
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Combination antiretroviral ther-apy can significantly prolong the life ex-pectancy of people living with human im-
munodeficiency virus (HIV), but HIV infection 
remains a chronic condition that requires lifelong 
daily oral treatment.1,2 Current antiretroviral regi-
mens are highly effective, and one focus of ongo-
ing drug development is improvement of the 
side-effect profile and convenience to reduce dis-
engagement from care. Prolonged daily regimens 
can engender dissatisfaction, contribute to stigma, 
and increase the risk of nonadherence to treat-
ment and treatment failure.3,4 Surveys indicate that 
many patients would prefer therapeutic alterna-
tives.5,6 Two-drug regimens have been developed 
as an option7,8; long-acting injectable regimens 
are another alternative that can free patients from 
the burden of daily regimens and potentially pro-
vide a more acceptable therapeutic approach.
Long-acting injectable formulations are being 
developed for cabotegravir, which is an integrase 
strand-transfer inhibitor (INSTI), and rilpivirine, 
which is a nonnucleoside reverse-transcriptase 
inhibitor (NNRTI) with an approved oral formu-
lation.9-11 In the Long-Acting Antiretroviral Treat-
ment Enabling Trial 2 (LATTE-2), participants 
who had not previously received antiretroviral 
therapy were given oral cabotegravir-based treat-
ment; those who had viral suppression were 
randomly assigned to continue oral treatment or 
switch to monthly intramuscular injections of 
long-acting cabotegravir plus rilpivirine. Viral 
suppression was maintained through week 96 in 
87% of the participants who switched to monthly 
long-acting therapy, as compared with 84% of the 
participants who continued oral therapy12; viral 
suppression was maintained through week 160 in 
83% of the recipients of long-acting therapy.13
The First Long-Acting Injectable Regimen 
(FLAIR) trial evaluated a potential pathway to 
long-acting injectable therapy for patients who 
had not previously received antiretroviral therapy. 
We assessed whether switching to monthly injec-
tions of long-acting cabotegravir plus rilpivirine 
would be noninferior to continuing oral therapy 
in patients with HIV type 1 (HIV-1) who had viral 
suppression in response to oral induction therapy.
Me thods
Trial Design and Participants
We designed this phase 3, randomized, multi-
center, open-label, noninferiority trial to have 
screening, induction, maintenance, extension, and 
long-term follow-up phases (Fig. 1A). Eligible 
participants were 18 years of age or older, had 
not previously received antiretroviral therapy, and 
had a plasma HIV-1 RNA level of 1000 copies per 
milliliter or higher at screening. The complete 
eligibility criteria are provided in the Supplemen-
tary Appendix and the protocol, available with 
the full text of this article at NEJM.org.
Participants received oral induction therapy 
with a fixed-dose combination of 50 mg of do-
lutegravir, 600 mg of abacavir, and 300 mg of 
lamivudine once daily for 20 weeks; those who 
had side effects in association with this therapy 
or were positive for HLA-B*5701 received doluteg-
ravir plus two nucleoside reverse-transcriptase 
inhibitors other than abacavir. Participants who 
had a plasma HIV-1 RNA level of less than 50 cop-
ies per milliliter after 16 weeks of oral induction 
therapy were randomly assigned, in a 1:1 ratio, 
to either continue the current oral therapy dur-
ing the maintenance phase or switch to long-
acting therapy for at least 100 weeks. Partici-
pants in the long-acting–therapy group received 
oral lead-in therapy with 30 mg of cabotegravir 
and 25 mg of rilpivirine once daily for approxi-
mately 4 weeks so that the safety and side-effect 
profile of the drugs could be confirmed before 
long-acting injectable therapy was begun. At 
week 4, the participants received loading injec-
tions of 600 mg of cabotegravir and 900 mg of 
rilpivirine (3 ml each), administered into the 
gluteus muscle. Subsequent injections of 400 mg 
of cabotegravir and 600 mg of rilpivirine (2 ml 
each) were administered within a window of 21 to 
28 days after the previous injection for the sec-
ond and third injections and a window of 21 to 35 
days thereafter. Oral bridging therapy with cabo-
tegravir and rilpivirine was available for partici-
pants who were unable to attend a visit for injec-
tions.
Participants who had confirmed virologic fail-
ure (two consecutive plasma HIV-1 RNA levels 
≥200 copies per milliliter) discontinued the as-
signed treatment. Participants who started long-
acting therapy and then discontinued the treat-
ment for any reason entered the 52-week 
follow-up phase and started an alternative, inves-
tigator-selected antiretroviral regimen.
The trial was conducted in accordance with 
the principles of the Declaration of Helsinki. All 
participants provided written informed consent, 
and institutional review boards at all sites ap-
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proved the protocol. The trial funders (ViiV 
Healthcare and Janssen Research and Develop-
ment) participated in the design of the trial and 
in the gathering, analysis, and interpretation of 
the data. All the authors vouch for the accuracy 
and completeness of the data and the fidelity of 
the trial to the protocol.
Randomization and Masking
A randomization sequence generated by Glaxo-
SmithKline-verified randomization software 
(RandAll NG, version 1.3.3) was used for treat-
ment assignments, with stratification according 
to the baseline (preinduction) HIV-1 RNA level 
(<100,000 or ≥100,000 copies per milliliter) and 
sex at birth. Central randomization, performed 
with blocks shared across sites, concealed the 
treatment schedule to prevent selection bias.
Procedures and End Points
Details regarding the trial assessments are pro-
vided in the Supplementary Appendix. The pri-
mary end point was the percentage of partici-
pants who had a plasma HIV-1 RNA level of 50 
copies per milliliter or higher at week 48 of the 
maintenance phase, determined with the use of 
the Food and Drug Administration (FDA) snap-
shot algorithm.14 The key secondary end point 
was the percentage of participants who had a 
plasma HIV-1 RNA level of less than 50 copies 
per milliliter at week 48 (FDA snapshot algo-
rithm). Other secondary end points included con-
firmed virologic failure, genotypic and pheno-
typic resistance coincident with virologic failure, 
CD4+ lymphocyte counts, graded adverse events,15 
laboratory abnormalities, plasma pharmacoki-
netics of cabotegravir and rilpivirine, treatment 
satisfaction scores, adherence to treatment, and 
virologic outcomes according to randomization 
strata and baseline subgroups. The baseline sub-
groups included post hoc subgroups defined 
according to the presence or absence of the L74I 
integrase polymorphism and the HIV-1 subtype 
distribution in each country.16 Treatment satis-
faction was measured with the use of the HIV 
Treatment Satisfaction Questionnaire, change 
version (HIVTSQc), at week 48.17 The HIVTSQc 
evaluates participants’ satisfaction with current 
antiretroviral therapy as compared with induc-
tion therapy; total scores range from −33 (much 
less satisfied now) to 33 (much more satisfied 
now). In an exploratory analysis, a single-item 
question regarding preference for long-acting or 
oral therapy at week 48 was evaluated in the 
long-acting–therapy group (Table S6 in the Sup-
plementary Appendix). A complete list of trial 
end points is provided in the Supplementary Ap-
pendix.
Statistical Analysis
The primary efficacy analysis included all partici-
pants who received at least one dose of the as-
signed trial drugs during the maintenance phase 
(intention-to-treat exposed population). For the 
primary and key secondary efficacy end points, 
the adjusted difference between treatment groups 
in the percentage of participants and correspond-
ing 95% confidence intervals were calculated 
on the basis of a stratified Cochran–Mantel–
Haenszel analysis, with adjustment for random-
ization stratification factors. The primary and 
key secondary efficacy end points were also as-
sessed in the per-protocol population, which ex-
cluded participants who had protocol deviations 
that were likely to affect efficacy assessments or 
lead to discontinuation of the trial drugs.
For the primary end point, noninferiority was 
concluded if the upper limit of a two-sided 95% 
confidence interval for the difference between 
the long-acting–therapy group and the oral-
therapy group in the percentage of participants 
who had an HIV-1 RNA level of 50 copies per 
milliliter or higher at week 48 was less than 
6 percentage points. The noninferiority margin 
of 6 percentage points was based on clinical 
considerations that balanced the potential ad-
vantages of long-acting therapy over daily oral 
therapy (e.g., treatment satisfaction and direct 
observation of treatment administration) with a 
clinically acceptable virologic failure rate: assum-
ing an observed virologic failure rate in the oral-
therapy group of 2%, we determined that nonin-
feriority of long-acting therapy would be shown 
if the observed difference between treatment 
groups was less than 3 percentage points. Fur-
thermore, the sample size allows 90% power to 
assess noninferiority with a more stringent mar-
gin of 4 percentage points with the use of 
pooled data from this trial and the Antiretroviral 
Therapy as Long Acting Suppression (ATLAS) 
trial, which involved patients who had previously 
received antiretroviral therapy.18
Assuming that the percentage of participants 
who had an HIV-1 RNA level of 50 copies per 
milliliter or higher at week 48 (FDA snapshot 
algorithm) would be 3% in the long-acting–
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631 Started the induction phase
809 Participants were assessed for eligibility
178 Were excluded owing
to screening failure
566 Were randomly assigned to therapy
in the maintenance phase
65 Were excluded before
randomization
283 Started lead-in therapy 283 Continued oral therapy
5 Discontinued lead-in therapy
2 Had adverse events
1 Withdrew
1 Was lost to follow-up
1 Had lack of efficacy





4 Had adverse events
3 Had lack of efficacy
2 Were lost to follow-up
1 Had protocol deviation
278 Started long-acting therapy
20 Discontinued long-acting
therapy
7 Had adverse events
6 Withdrew
4 Had lack of efficacy
2 Were withdrawn
by physician
1 Was lost to follow-up
258 Continued ongoing study 261 Continued ongoing study
−20 −4 Day
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Monthly injections of long-acting CAB+
long-acting RPV 
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therapy group and 2% in the oral-therapy group, 
with a noninferiority margin of 6 percentage 
points and a one-sided significance level of 
2.5%, we calculated that a sample of 285 par-
ticipants per treatment group would give the 
trial approximately 97% power to show noninfe-
riority of long-acting therapy to oral therapy 
with regard to the primary end point. This 
sample size would also provide more than 94% 
power to show noninferiority with regard to the 
key secondary end point, with the assumption of 
a response rate of 87% with each treatment, a 
noninferiority margin of −10 percentage points, 
and a one-sided significance level of 2.5%.
R esult s
Participants
A total of 809 adults were screened at 108 sites 
in 11 countries beginning on October 27, 2016 
(Fig. 1B); the last participant completed week 48 
on August 30, 2018. Oral induction therapy was 
initiated in 629 participants; 63 of those partici-
pants withdrew from the trial before randomiza-
tion, primarily because of a lack of efficacy, and 
the remaining 566 were randomly assigned to 
treatment in the maintenance phase (283 to each 
treatment group). During the maintenance phase, 
25 participants (9%) in the long-acting–therapy 
group and 22 participants (8%) in the oral-
therapy group withdrew from the trial; with-
drawals were most frequently due to adverse 
events in the long-acting–therapy group (in 9 par-
ticipants) and participant decision to withdraw 
in the oral-therapy group (in 7). In the long-
acting–therapy group, 98% of the 3577 expected 
injection visits (12 per participant by week 48, 
with additional visits beyond week 48) occurred 
within a window of 21 to 35 days after the previ-
ous injection; four of five missed injections were 
covered with oral bridging therapy (Fig. S1). In the 
oral-therapy group, adherence to treatment was 
more than 90% on the basis of patient-reported 
treatment interruptions of 3 or more consecu-
tive days.
Across the two treatment groups, participants 
were a median of 34 years of age, 22% were fe-
male, and 74% were white; approximately 20% 
had an HIV-1 RNA level of 100,000 copies per 
milliliter or higher at baseline (Table 1). Before 
the induction phase, 69% of the participants had 
a CD4+ lymphocyte count of 350 per microliter 
or higher, and this percentage increased to 90% 
by the start of maintenance therapy.
Efficacy
At week 48, an HIV-1 RNA level of 50 copies per 
milliliter or higher was found in 6 participants 
(2.1%) who received long-acting therapy and in 
7 participants (2.5%) who received oral therapy 
(adjusted difference, −0.4 percentage points; 
95% confidence interval [CI], −2.8 to 2.1), a re-
sult that met the prespecified noninferiority 
criterion for the primary end point (Table 2). For 
this end point, there was no meaningful esti-
Figure 1 (facing page). Trial Design, Screening, 
 Randomization, and Treatment.
Panel A shows the trial design scheme, which includes 
screening, induction, maintenance, and extension 
phases. During the screening phase, adults who met 
the inclusion criteria were enrolled in the trial; key ex‑
clusion criteria were previous use of antiretroviral ther‑
apy (ART), detection of hepatitis B virus (HBV) surface 
antigen, and the presence of nonnucleoside reverse‑
transcriptase inhibitor (NNRTI) resistance mutations 
other than the K103N mutation. During the induction 
phase, a single‑tablet regimen of dolutegravir, abacavir, 
and lamivudine (DTG–ABC–3TC) was administered 
once daily for 20 weeks; those who had side effects in 
association with this therapy or were positive for HLA‑
B*5701 received dolutegravir plus two nucleoside re‑
verse‑transcriptase inhibitors other than abacavir. Dur‑
ing randomization, participants were randomly assigned 
to continue the current oral therapy or switch to long‑
acting therapy during the maintenance phase. Partici‑
pants in the long‑acting–therapy group received oral 
lead‑in therapy with cabotegravir (CAB) plus rilpivirine 
(RPV), followed by injections of long‑acting formula‑
tions: initial loading injections of 600 mg of cabotegravir 
and 900 mg of rilpivirine were administered at week 4, 
and subsequent injections of 400 mg of cabotegravir 
and 600 mg of rilpivirine were administered every 4 weeks 
beginning at week 8. In this ongoing trial, participants 
who discontinue or complete long‑acting therapy enter 
a 52‑week long‑term follow‑up phase. Participants in 
the oral‑therapy group who maintain viral suppression 
have the option to switch to long‑acting therapy during 
the extension phase. Panel B shows participants who 
underwent screening, randomization, and treatment. 
Overall, 566 adults were randomly assigned to treat‑
ment; 180 adults who underwent screening were not 
assigned to treatment, primarily because they did not 
meet the eligibility requirements (149 participants). Of 
those 180 participants, 65 were excluded from the trial 
before randomization, primarily because they did not 
meet the viral suppression criterion while receiving oral 
induction therapy; 2 withdrew before receiving induction 
therapy. Treatment was initiated in 283 participants in 
each treatment group (intention‑to‑treat exposed popu‑
lation). The safety and intention‑to‑treat exposed popu‑
lations were identical.
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mated difference between treatments across sub-
groups (Fig. S2). Similarly, long-acting therapy 
was noninferior to oral therapy with regard to 
the key secondary end point of the percentage of 
participants with an HIV-1 RNA level of less 
than 50 copies per milliliter at week 48 (93.6% 
and 93.3%, respectively; adjusted difference, 0.4 
percentage points; 95% CI, −3.7 to 4.5). On tests 
for evidence against homogeneity in the differ-
ences between treatments across randomization 
strata, results were not significant. All these re-
sults were similar in the per-protocol population 
(Table 2).
In the long-acting–therapy group, 4 partici-
pants had confirmed virologic failure. In 1 of 
those participants (who had HIV-1 subtype AG), 
oral lead-in therapy was suspended owing to a 
false-positive pregnancy test; on reinitiation of 
oral therapy, criteria for confirmed virologic 
failure were met and the participant was with-
drawn from the trial before long-acting therapy 
was initiated, with no resistance mutations de-
tected. The other 3 participants had NNRTI and 
INSTI resistance mutations (Table S1) that devel-
oped during long-acting therapy; these mutations 
reduced susceptibility to rilpivirine in 2 partici-
pants by a factor of more than 2 and reduced 
susceptibility to cabotegravir in all 3 participants 
by a factor of more than 5. These 3 participants 
had HIV-1 subtype A1 with the L74I integrase 
polymorphism at baseline. However, 51 of the 
54 participants in the long-acting–therapy group 








Median age (range) — yr 34 (19–68) 34 (18–68) 34 (18–68)
Age group — no. (%)
<35 yr 143 (51) 145 (51) 288 (51)
35 to <50 yr 107 (38) 109 (39) 216 (38)
≥50 yr 33 (12) 29 (10) 62 (11)
Female sex — no. (%) 63 (22) 64 (23) 127 (22)
Race — no. (%)†
White 216 (76) 201 (71) 417 (74)
Black 47 (17) 56 (20) 103 (18)
Other 20 (7) 24 (8) 44 (8)
Missing 0 2 (1) 2 (<1)
Median body‑mass index (range)‡ 24 (17–45) 24 (13–47) 24 (13–47)
HIV‑1 RNA level — no. (%)
<1000 copies/ml 9 (3) 5 (2) 14 (2)
1000 to <10,000 copies/ml 64 (23) 71 (25) 135 (24)
10,000 to <50,000 copies/ml 95 (34) 113 (40) 208 (37)
50,000 to <100,000 copies/ml 59 (21) 38 (13) 97 (17)
100,000 to <200,000 copies/ml 30 (11) 33 (12) 63 (11)
≥200,000 copies/ml 26 (9) 23 (8) 49 (9)
CD4+ lymphocyte count — no. (%)
<200 per μl 16 (6) 23 (8) 39 (7)
200 to <350 per μl 71 (25) 64 (23) 135 (24)
350 to <500 per μl 88 (31) 88 (31) 176 (31)
≥500 per μl 108 (38) 108 (38) 216 (38)
*  Percentages may not total 100 because of rounding.
†  Race was reported by the participant.
‡  Body‑mass index is the weight in kilograms divided by the square of the height in meters.
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who had HIV-1 with the L74I integrase polymor-
phism at baseline did not have virologic failure 
(Table S2). In subgroup analyses of the primary 
end point, no significant difference between 
treatments was observed in subgroups defined 
according to the presence or absence of the L74I 
integrase polymorphism or according to HIV-1 
subtype (Fig. S2). In the oral-therapy group, 3 par-
ticipants had confirmed virologic failure without 
the development of resistance mutations or phe-
notypic changes during treatment. In the primary 
analysis, 2 participants who received long-acting 
therapy and 4 participants who received oral ther-
apy had an HIV-1 RNA level of 50 copies per 
milliliter or higher without confirmed virologic 
failure; neither of the participants who received 
long-acting therapy had HIV-1 resistance muta-
tions.
Safety and Side Effects
During the maintenance phase, the most com-
mon adverse events in the long-acting–therapy 












HIV‑1 RNA level — no. (%)
<50 copies/ml 265 (93.6) 264 (93.3) 0.4 (−3.7 to 4.4) 0.4 (−3.7 to 4.5)
≥50 copies/ml†  6 (2.1)  7 (2.5) −0.4 (−2.8 to 2.1) −0.4 (−2.8 to 2.1)
Level not below threshold  2 (0.7)  2 (0.7) — —
Discontinued treatment for lack of efficacy  4 (1.4)  3 (1.1) — —
Discontinued treatment for other reasons 0  2 (0.7) — —
No virologic data 12 (4.2) 12 (4.2) — —
Withdrew from trial owing to adverse event 
or death
 8 (2.8)  2 (0.7) — —
Withdrew from trial for other reasons  4 (1.4) 10 (3.5) — —
Subgroup analysis of HIV‑1 RNA level ≥50 copies/
ml — no./total no. (%)‡
Sex at birth
Female 3/63 (4.8) 1/64 (1.6) 3.2 (−4.3 to 12.0) —
Male 3/220 (1.4) 6/219 (2.7) −1.4 (−4.7 to 1.6) —
Baseline HIV‑1 RNA level
<100,000 copies/ml 4/227 (1.8) 5/227 (2.2) −0.4 (−3.6 to 2.5) —
≥100,000 copies/ml 2/56 (3.6) 2/56 (3.6) 0.0 (−9.2 to 9.2) —
Per-protocol population§
HIV‑1 RNA level — no./total no. (%)
<50 copies/ml 260/278 (93.5) 263/282 (93.3) 0.3 (−3.9 to 4.4) 0.3 (−3.8 to 4.4)
≥50 copies/ml 6/278 (2.2) 7/282 (2.5) −0.3 (−2.8 to 2.2) −0.3 (−2.8 to 2.2)
*  Values are based on a stratified Cochran–Mantel–Haenszel analysis, with adjustment for sex at birth and baseline (preinduction) human 
 immunodeficiency virus type 1 (HIV‑1) RNA level.
†  A level of 50 copies per milliliter or higher was observed at week 48 (level not below threshold) or at the time of treatment discontinuation 
before week 48.
‡  Separate tests of homogeneity in the differences between treatments across randomization strata were conducted with the use of a weighted 
least‑squares chi‑square statistic and a 10% one‑sided significance level. The 95% confidence intervals for differences across subgroups 
were calculated with the use of an unconditional exact method with two inverted one‑sided tests.
§  The per‑protocol population excluded 5 participants in the long‑acting–therapy group (2 who received treatment outside the permitted window, 
2 who had HIV‑1 RNA samples that were compromised at the central laboratory, and 1 who received a prohibited HIV‑1 medication before 
the baseline visit) and 1 participant in the oral‑therapy group (who received prohibited medications).
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group, excluding injection-site reactions, were 
nasopharyngitis, headache, upper respiratory tract 
infection, and diarrhea (Table 3 and Table S3). 
Serious adverse events occurred in 18 partici-
pants (6%) who received long-acting therapy and 
in 12 participants (4%) who received oral therapy 
(Table S4); each type of event occurred in 1 par-
ticipant (except hepatitis A, which occurred in 
3 participants who received long-acting therapy), 
with no deaths. Adverse events that led to with-
drawal from the trial occurred in 9 participants 
(3%) who received long-acting therapy and in 
4 participants (1%) who received oral therapy. In 
the long-acting–therapy group, the only events 
that led to withdrawal in more than 1 participant 
were viral hepatitis and injection-site pain (in 5 and 
2 participants, respectively) (Table S5). During the 
maintenance phase, events that met liver-related 
stopping criteria occurred in 7 participants (2%) 
who received long-acting therapy and in 2 par-
ticipants (1%) who received oral therapy, includ-
ing eight cases of acute viral hepatitis and one 
case of inorganic solvent toxicity. One partici-
pant in the oral-therapy group was pregnant and 
had a healthy baby. At week 48, the median 
weight gain from baseline was 1.3 kg (interquar-
tile range, −1.0 to 5.0) in the long-acting–therapy 
group and 1.5 kg (interquartile range, −1.0 to 3.9) 
in the oral-therapy group.
Of the participants who received long-acting 
therapy, 86% had at least one injection-site reac-
tion. The most common injection-site reaction 
was pain, which was reported by 227 of the 278 
participants (82%) who received at least one in-
jection (Table S3). Most of the 1879 pain events 
were of mild or moderate severity (86% and 
13%, respectively); 12 events (<1%) in 11 partici-
pants were severe (grade 3), and there were no 
grade 4 events. The incidence of injection-site 
reactions was highest (71%) after the initial 3-ml 
injections at week 4 and subsequently decreased 
to 20% at week 48 (Fig. S3). The median duration 
of injection-site reactions was 3 days; 88% of 
cases resolved within 7 days. Injection-site reac-
tions led to withdrawal from the trial in 2 par-
ticipants, and another 2 participants withdrew 
consent for other injection-related reasons. Other 
adverse events that were considered by investiga-
tors to be drug-related were more common with 
long-acting therapy than with oral therapy (oc-
curring in 28% vs. 10% of the participants). 
There was no discernible pattern to these events; 
other than injection-site reactions, the most 
common drug-related events (occurring in ≥5% 
of the participants) in the long-acting–therapy 
group were headache and pyrexia.
Pharmacokinetics
Plasma concentrations of cabotegravir and rilpi-
virine during long-acting therapy (Fig. 2) were 
similar to the concentrations reported during 
oral therapy.19,20 The geometric mean cabotegra-
vir trough concentration was 1.56 μg per milli-
liter at week 8 and 3.13 μg per milliliter at week 
48; these concentrations are 9.4 times and 18.9 
times, respectively, as high as the in vitro protein-
adjusted 90% inhibitory concentration (PA-IC90) 
for the drug. The geometric mean rilpivirine 
trough concentration was 41.2 ng per milliliter 
at week 8 and 82.4 ng per milliliter at week 48; 
these concentrations are 3.4 times and 6.9 times 
as high as the PA-IC90. The three participants who 
received long-acting therapy and had confirmed 
virologic failure had cabotegravir and rilpivirine 
concentrations in the lowest quartile, with one 
having drug concentrations below the fifth per-
centile (Fig. S4); all three had a body-mass index 
(the weight in kilograms divided by the square 
of the height in meters) of more than 30 at base-
line, but none missed an injection or received 
injections outside the permitted window.
Patient-Reported Outcomes
At week 48, the HIVTSQc total score for satisfac-
tion with current treatment as compared with 
induction treatment was higher in the long-act-
ing–therapy group than in the oral-therapy group 
(adjusted mean difference, 4.1 points; 95% CI, 
2.8 to 5.5) (Table S7). An exploratory analysis of 
a single-item question regarding therapy prefer-
ence at week 48 indicated that 257 of 283 par-
ticipants (91%) who received long-acting therapy 
in the intention-to-treat exposed population and 
257 of 259 participants (99%) who responded to 
the survey preferred the long-acting regimen 
over the previous oral therapy.
Discussion
The results of this trial show a pathway for pa-
tients who have not previously received anti-
retroviral therapy to reach and maintain HIV-1 
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number of participants (percent)
Any adverse event 267 (94) 225 (80)
Any adverse event, excluding injection‑site reactions 246 (87) 225 (80)
Grade ≥3 adverse events 31 (11) 11 (4)
Grade ≥3 adverse events, excluding injection‑site reactions 22 (8) 11 (4)
Adverse events that led to withdrawal from the trial† 9 (3) 4 (1)
Serious adverse events‡ 18 (6) 12 (4)
Adverse events that led to death 0 0
Drug‑related adverse events
Any 236 (83) 28 (10)
Any, excluding injection‑site reactions§ 79 (28) 28 (10)
Grade ≥3 14 (5) 0
Grade ≥3, excluding injection‑site reactions¶ 4 (1) 0
Injection‑site pain
Any 227 (80) NA
Grade ≥3 11 (4) NA
Adverse events reported in ≥5% of participants in either 
treatment group, excluding injection‑site reactions
Nasopharyngitis 56 (20) 48 (17)
Headache 39 (14) 21 (7)
Upper respiratory tract infection 38 (13) 28 (10)
Diarrhea 32 (11) 25 (9)
Influenza 25 (9) 20 (7)
Vitamin D deficiency 23 (8) 13 (5)
Back pain 22 (8) 13 (5)
Pyrexia 22 (8) 4 (1)
Hemorrhoids 16 (6) 3 (1)
Nausea 16 (6) 11 (4)
Dizziness 15 (5) 3 (1)
Gastroenteritis 15 (5) 11 (4)
Pharyngitis 15 (5) 9 (3)
*  NA denotes not applicable.
†  The most common events that led to withdrawal in the long‑acting–therapy group were acute hepatitis B (in 2 partici‑
pants), hepatitis A (2), and injection‑site pain (2); 1 of the participants with hepatitis B had inadequate antibody titers 
after vaccination. All other adverse events that led to withdrawal were reported in 1 participant each.
‡  The most common serious adverse event in the long‑acting–therapy group was hepatitis A, which was reported in  
3 participants, 2 of whom withdrew from the trial. All other serious adverse events were reported in 1 participant each.
§  Other than injection‑site reactions, the most common adverse events that were considered by investigators to be possi‑
bly or probably related to long‑acting therapy were headache (in 14 participants), pyrexia (13), increased body temper‑
ature (8), asthenia (7), and malaise (5). The most common drug‑related events in the oral‑therapy group were nausea 
(in 6 participants) and fatigue (5).
¶  In the long‑acting–therapy group, 3 participants had grade 3 events of night sweats, right knee monoarthritis, and poor‑
quality sleep; 1 participant had a grade 4 elevated lipase level.
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suppression with oral induction therapy and a 
subsequent transition to monthly injectable ther-
apy. After viral suppression was achieved with a 
standard oral INSTI-based regimen, the simpli-
fied injectable regimen, which consisted of long-
acting formulations of cabotegravir and rilpivi-
rine, was noninferior to continued oral therapy 
with regard to maintaining suppression through 
week 48.
Baseline viral load had no significant effect 
on the results for the primary end point; this 
finding suggests that if the viral load is sup-
pressed without evidence of cabotegravir or rilpi-
virine resistance mutations, a transition to long-
acting therapy is feasible. At baseline, HIV-1 
subtype A1 was present in 8 participants in the 
long-acting–therapy group, 5 of whom main-
tained viral suppression and 3 of whom had viro-
logic failure. All 3 of the participants who had 
virologic failure during long-acting therapy also 
had a body-mass index of more than 30, plasma 
drug levels in the lowest quartile, and HIV-1 
with the L74I integrase polymorphism. However, 
the L74I integrase polymorphism does not con-
fer resistance to cabotegravir by itself: 51 of 54 
participants in the long-acting–therapy group 
who had the L74I integrase polymorphism did 
not have virologic failure at week 48.21,22 No dos-
ing complications that may have contributed to 
virologic failure were reported. With virologic 
failure occurring in only 4 participants in the 
long-acting–therapy group (and occurring before 
the initiation of long-acting therapy in 1 of those 
participants), the potential contributions of viro-
logic, pharmacokinetic, demographic, and other 
factors to virologic outcomes remain uncertain; 
future analyses of pooled study data may provide 
clarification.
The three-drug combination of dolutegravir, 
abacavir, and lamivudine that was used for induc-
tion therapy and as the control regimen during 
the maintenance phase is a recommended first-
line regimen for patients who have not previously 
received antiretroviral therapy.23 Efficacy results 
with long-acting therapy in this trial were simi-
lar to those seen in the ATLAS trial, which had 
a similar switch design but enrolled participants 
who had longer-term viral suppression, which 
had been achieved with the use of other stan-
dard three-drug oral therapies.18 Together, the 
FLAIR and ATLAS trials show that the long-
acting regimen effectively maintained viral sup-
pression that had initially been achieved with 
the use of oral regimens, both in adults new to 
treatment and in those who had received pro-
longed previous treatment.
Other than injection-site reactions, no patterns 
of adverse events with the long-acting regimen 
were evident, a finding consistent with the re-
ported safety profiles of oral cabotegravir and 
rilpivirine.12,20 Injection-site reactions, primarily 
pain, were common, but the incidence decreased 
from 71% to 20% during the trial. Injection-site 
Figure 2. Plasma Concentration–Time Profiles.
Shown are the median plasma concentration–time profiles for cabotegravir 
(Panel A) and rilpivirine (Panel B) in 278 participants who received monthly 
injections of long‑acting therapy. I bars indicate the 5th and 95th percentiles. 
Dashed lines indicate the in vitro protein‑adjusted 90% inhibitory concen‑
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reactions were generally of mild or moderate 
severity and transient; 4 of the 283 participants 
in the long-acting–therapy group withdrew from 
the trial owing to injection-site reactions or 
other injection-related reasons. The incidences 
of some adverse events other than injection-site 
reactions were higher in the long-acting–therapy 
group than in the oral-therapy group; however, 
effects associated with starting a new treatment 
(as opposed to continuing the same treatment) 
may have contributed to the observed differences 
— a possibility consistent with observations in 
previous switch studies.8,24
The long-acting regimen was preferred over 
the previous oral therapy by 91% of recipients, 
even after 12 monthly injections. Conclusions 
derived from this finding are limited to patients 
who are willing to consider injectable therapy, 
reflecting the enrolled trial population. Similarly, 
in clinical practice, the long-acting regimen is a 
therapeutic option that patients can select ac-
cording to their preference. For patients who 
choose long-acting therapy, the data regarding 
treatment preference suggest that their expecta-
tions of regimen benefits will be met.
The potential clinical role of the long-acting 
regimen remains to be fully defined for the 
spectrum of patients with HIV-1 infection, par-
ticularly those who have adherence challenges, 
in different practice settings. In this regard, ad-
ditional randomized efficacy and safety trials of 
the long-acting regimen include the ATLAS trial,18 
which enrolled participants who had previously 
received antiretroviral therapy, and the LATITUDE 
trial (ClinicalTrials.gov number, NCT03635788), 
which enrolled participants who had adherence 
difficulties. Ongoing follow-up of the FLAIR and 
ATLAS trials will assess outcomes of long-acting 
therapy extended beyond 48 weeks. Several ad-
ditional ongoing or planned studies (e.g., the 
Cabotegravir plus Rilpivirine in the U.S. to Opti-
mize and Measure Implementation and Experi-
ence [CUSTOMIZE] trial; NCT04001803) are fo-
cused on implementation of the long-acting 
regimen in various settings, including university 
hospitals and private and public health clinics.
In conclusion, monthly two-drug long-acting 
therapy was noninferior to standard three-drug 
oral therapy with regard to maintaining viral 
suppression for 48 weeks in adults with HIV-1 
infection who had not previously received anti-
retroviral therapy, with greater reported treat-
ment satisfaction.
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